Bevacizumab and Gemcitabine in Treating Patients With Advanced Pancreatic Cancer

NCT00028834 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

NIH

Sponsor class

Conditions

Adenocarcinoma of the Pancreas
Recurrent Pancreatic Cancer
Stage III Pancreatic Cancer
Stage IV Pancreatic Cancer

Interventions

DRUG: gemcitabine hydrochloride
BIOLOGICAL: bevacizumab
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)